Climb Bio, Inc. Common Stock (CLYM) is a publicly traded Healthcare sector company. As of July 28, 2026, CLYM trades at $12.83 with a market cap of $735.26M and a P/E ratio of -14.13. CLYM moved -0.39% today. Year to date, CLYM is +219.75%; over the trailing twelve months it is +782.07%. Its 52-week range spans $1.05 to $14.42. Analyst consensus is strong buy with an average price target of $22.71. Rallies surfaces CLYM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CLYM financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CLYM recently traded at $12.83. Market cap is $735.26M. P/E ratio is -14.13. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $12.83 |
| Market Cap | $735.26M |
| P/E Ratio | -14.13 |
| EPS | $-0.88 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.42 |
| 52-Week Low | $1.05 |
| Volume | 1.11M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-59.85M |
| Gross Margin | 0.00% |
12 analysts cover CLYM: 0 strong buy, 12 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $22.71.